Back to News
Market Impact: 0.35
BioNTech Continues AHEAD-MERIT Trial Despite BNT113's PFS Endpoint Miss
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCompany Fundamentals
BioNTech said its Phase 2/3 AHEAD-MERIT trial of BNT113 plus pembrolizumab did not meet its primary endpoint of progression-free survival compared with pembrolizumab alone in patients with HPV16-positive head and neck cancer. The provided article text gives no further efficacy, safety, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
BNTX-0.85
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Wells Fargo CFO on Earnings, Deals, Consumer Strength
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- We're upgrading our Goldman Sachs rating after a strong quarter bodes well for the future